Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

The First Affiliated Hospital of Dalian Medical University

Status: Completed

Conditions: Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Aged; Dual Anti-Platelet Therapy

Treatments: Drug: Ticagrelor

Study type: Observational

Funder types: Other

Identifiers

NCT04999293

PJ-KS-KY-2021-146

Details and patient eligibility

About

The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.

Enrollment: 1,505 patients

Sex: All

Ages: 75+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age≥75 years old;
• Treated with PCI (limited to stent implantation) ;
• Survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at discharge;

Exclusion criteria

• Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization;
• Concurrent use of oral anticoagulants;
• Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency;
• Acute infectious diseases;
• Cognitive impairment;
• Declined re-examination.

Trial design

1,505 participants in 1 patient group

The Elderly Undergoing Percutaneous Coronary Intervention

Description:

Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.

Treatment:

Drug: Ticagrelor